- Home
- SUPN vs ECAT Comparison
SUPN vs ECAT Comparison
Compare SUPN & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- ECAT
- Stock Information
- Founded
- SUPN 2005
- ECAT 2021
- Country
- SUPN United States
- ECAT United States
- Employees
- SUPN N/A
- ECAT N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- SUPN Health Care
- ECAT Finance
- Exchange
- SUPN Nasdaq
- ECAT Nasdaq
- Market Cap
- SUPN 1.9B
- ECAT 1.8B
- IPO Year
- SUPN 2012
- ECAT N/A
- Fundamental
- Price
- SUPN $36.43
- ECAT $16.39
- Analyst Decision
- SUPN Hold
- ECAT
- Analyst Count
- SUPN 1
- ECAT 0
- Target Price
- SUPN $36.00
- ECAT N/A
- AVG Volume (30 Days)
- SUPN 348.4K
- ECAT 278.6K
- Earning Date
- SUPN 02-25-2025
- ECAT 01-01-0001
- Dividend Yield
- SUPN N/A
- ECAT 9.20%
- EPS Growth
- SUPN 130.79
- ECAT N/A
- EPS
- SUPN 1.07
- ECAT 2.39
- Revenue
- SUPN $651,972,000.00
- ECAT N/A
- Revenue This Year
- SUPN $7.82
- ECAT N/A
- Revenue Next Year
- SUPN N/A
- ECAT N/A
- P/E Ratio
- SUPN $34.05
- ECAT $7.15
- Revenue Growth
- SUPN 6.79
- ECAT N/A
- 52 Week Low
- SUPN $25.53
- ECAT $14.02
- 52 Week High
- SUPN $39.37
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- SUPN 52.26
- ECAT 31.61
- Support Level
- SUPN $35.73
- ECAT $16.40
- Resistance Level
- SUPN $37.34
- ECAT $17.16
- Average True Range (ATR)
- SUPN 1.20
- ECAT 0.27
- MACD
- SUPN -0.01
- ECAT -0.08
- Stochastic Oscillator
- SUPN 69.02
- ECAT 2.22
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.